Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Clinical and Translational Science
|
February 20, 2025
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis
Ashley L Lennox, Libo Sun, Fei Huang, et al.
Clinical Pharmacology in Drug Development
|
August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects
Peter N Morcos, Neil Parrott, Ludger Banken, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
May 17, 2016
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects
Peter N Morcos, Li Yu, Katrijn Bogman, et al.
Hepatology International
|
February 18, 2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Edward J Gane, Régine Rouzier, Tarek Hassanein, et al.
Cancer Research Communications
|
February 10, 2025
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial
Rafal Dziadziuszko, Solange Peters, Tony Mok, et al.
The Lancet. Respiratory Medicine
|
April 15, 2019
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, et al.
Antimicrobial Agents and Chemotherapy
|
December 4, 2013
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders
Edward J Gane, Régine Rouzier, Alicja Wiercinska-Drapalo, et al.
The New England Journal of Medicine
|
June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters, D Ross Camidge, Alice T Shaw, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 13, 2014
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
Edward J Gane, Paul J Pockros, Stefan Zeuzem, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Clinical and Translational Science
|
February 20, 2025
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis
Ashley L Lennox, Libo Sun, Fei Huang, et al.
Clinical Pharmacology in Drug Development
|
August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects
Peter N Morcos, Neil Parrott, Ludger Banken, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
May 17, 2016
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects
Peter N Morcos, Li Yu, Katrijn Bogman, et al.
Hepatology International
|
February 18, 2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Edward J Gane, Régine Rouzier, Tarek Hassanein, et al.
Cancer Research Communications
|
February 10, 2025
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial
Rafal Dziadziuszko, Solange Peters, Tony Mok, et al.
The Lancet. Respiratory Medicine
|
April 15, 2019
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, et al.
Antimicrobial Agents and Chemotherapy
|
December 4, 2013
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders
Edward J Gane, Régine Rouzier, Alicja Wiercinska-Drapalo, et al.
The New England Journal of Medicine
|
June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters, D Ross Camidge, Alice T Shaw, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 13, 2014
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
Edward J Gane, Paul J Pockros, Stefan Zeuzem, et al.
Page
of 6